Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Total Liabilities for 16 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 3.99% to $46.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.8 million, a 3.99% decrease, with the full-year FY2025 number at $46.8 million, down 3.99% from a year prior.
  • Total Liabilities was $46.8 million for Q4 2025 at Anika Therapeutics, up from $42.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $85.6 million in Q1 2021 to a low of $40.0 million in Q2 2025.
  • A 5-year average of $57.4 million and a median of $57.1 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 52.33% in 2021, then grew 8.92% in 2023.
  • Anika Therapeutics' Total Liabilities stood at $60.4 million in 2021, then grew by 5.15% to $63.6 million in 2022, then decreased by 8.18% to $58.4 million in 2023, then fell by 16.48% to $48.8 million in 2024, then dropped by 3.99% to $46.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Total Liabilities are $46.8 million (Q4 2025), $42.6 million (Q3 2025), and $40.0 million (Q2 2025).